Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline Licenses Software Kit from Merck s Rosetta Biosoftware

NEW YORK, Oct. 8 — Rosetta Biosoftware, the new business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck, and Agilent, the distributor of Rosetta software, said on Monday that GlaxoSmithKline is the first licensee of version 2.0 of the Rosetta Resolver Software Development Kit. The kit enables users of the Resolver gene expression data storage and analysis program to access the system's open application program interfaces in order to enhance and customize the product. According to Rosetta Biosoftware, users can incorporate their own error models and clustering algorithms via the system's open APIs. Error models are plugged in using Java technology, while clustering algorithms are incorporated using both C++ and Java.

Paul Matthews, project leader of gene expression bioinformatics at GlaxoSmithKline, which has been a customer of the Resolver software, said in a statement that his internal bioinformatics staff would make use of the open system to integrate it with Glaxo’s internally developed algorithms and bioinformatics tools. 

Barney Saunders, vice president and general manager of Agilent's life sciences division, said,  "Allowing customers access to the system's APIs is part of our commitment to provide tools that will most efficiently help our customers achieve their research goals." 

Other Rosetta Resolver customers include Biogen, Bristol-Myers Squibb, and Merck. Merck acquired Rosetta Inpharmatics in May, and Rosetta spun off the Biosoftware  business unit in September.

 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.